|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/03/14 Allscripts Healthcare Soluti… Inc 10-K 12/31/13 132:13M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.51M
2: EX-10.29 Material Contract HTML 81K
3: EX-10.31 Material Contract HTML 39K
4: EX-10.39 Material Contract HTML 110K
5: EX-10.40 Material Contract HTML 109K
6: EX-10.43 Material Contract HTML 84K
8: EX-21.1 Subsidiaries List HTML 38K
9: EX-23.1 Consent of Experts or Counsel HTML 40K
7: EX-12.1 Statement re: Computation of Ratios HTML 53K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 41K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 41K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 36K
89: R1 Document and Entity Information HTML 66K
67: R2 Consolidated Balance Sheets HTML 146K
84: R3 Consolidated Balance Sheets (Parenthetical) HTML 62K
93: R4 Consolidated Statements of Operations HTML 101K
120: R5 Consolidated Statements of Comprehensive Income HTML 69K
(Loss)
71: R6 Consolidated Statements of Stockholders' Equity HTML 97K
83: R7 Consolidated Statements of Cash Flows HTML 151K
61: R8 Consolidated Statements of Cash Flows HTML 36K
(Parenthetical)
50: R9 Basis of Presentation and Significant Accounting HTML 177K
Policies
122: R10 Business Combinations HTML 75K
95: R11 Fixed Assets HTML 52K
94: R12 Goodwill and Intangible Assets HTML 94K
102: R13 Asset Impairment Charges HTML 42K
103: R14 Accrued Expenses HTML 42K
99: R15 Debt HTML 106K
104: R16 Income Taxes HTML 148K
85: R17 Stock Award Plans HTML 130K
90: R18 Stockholders' Equity HTML 50K
97: R19 Accumulated Other Comprehensive Income HTML 47K
131: R20 Derivative Financial Instruments HTML 64K
113: R21 Commitments HTML 54K
77: R22 Business Segments HTML 73K
96: R23 Supplemental Disclosure of Cash Flow Information HTML 43K
80: R24 Geographic Information HTML 52K
40: R25 Contingencies HTML 50K
114: R26 Commitment with Strategic Partner HTML 44K
127: R27 North American Site Consolidation Plan HTML 40K
55: R28 Schedule II-Valuation and Qualifying Accounts HTML 47K
54: R29 Basis of Presentation and Significant Accounting HTML 236K
Policies (Policies)
59: R30 Basis of Presentation and Significant Accounting HTML 125K
Policies (Tables)
60: R31 Business Combinations (Tables) HTML 69K
62: R32 Fixed Assets (Tables) HTML 53K
28: R33 Goodwill and Intangible Assets (Tables) HTML 92K
111: R34 Asset Impairment Charges (Tables) HTML 40K
75: R35 Accrued Expenses (Tables) HTML 41K
78: R36 Debt (Tables) HTML 90K
45: R37 Income Taxes (Tables) HTML 149K
130: R38 Stock Award Plans (Tables) HTML 117K
19: R39 Accumulated Other Comprehensive Income (Tables) HTML 47K
64: R40 Derivative Financial Instruments (Tables) HTML 47K
118: R41 Commitments (Tables) HTML 55K
42: R42 Business Segments (Tables) HTML 63K
53: R43 Supplemental Disclosure of Cash Flow Information HTML 41K
(Tables)
58: R44 Geographic Information (Tables) HTML 57K
69: R45 Commitment with Strategic Partner (Tables) HTML 40K
27: R46 Basis of Presentation and Significant Accounting HTML 85K
Policies - Additional Information (Detail)
49: R47 Reimbursements for Out-of-Pocket Expenses Incurred HTML 38K
as Professional Services Revenue (Detail)
21: R48 Revenue Earned on Contracts in Excess of Billings HTML 42K
Included in Accounts Receivable and Other Assets
(Detail)
116: R49 Summary of Financial Assets and Liabilities HTML 69K
Measured at Fair Value on Recurring Basis (Detail)
41: R50 Unamortized Balances of Capitalized Software HTML 43K
(Detail)
112: R51 Capitalized Software Development Costs, Write Offs HTML 44K
and Amortization of Capitalized Software
Development Costs Included in System Sales Cost of
Revenue (Detail)
46: R52 Calculations of (Loss) Earnings Per Share (Detail) HTML 65K
65: R53 Anti-Dilutive Stock Options, Restricted Stock Unit HTML 39K
Awards and Warrants Excluded from Computation of
Diluted (Loss) Earnings Per Share (Detail)
20: R54 Company Contributions to Employee Benefit Plan HTML 37K
(Detail)
24: R55 Business Combinations - Additional Information HTML 121K
(Detail)
57: R56 Fair Value of Consideration Transferred for HTML 51K
Acquisition (Detail)
32: R57 Fair Value of Consideration Transferred for HTML 46K
Acquisition (Parenthetical) (Detail)
123: R58 Assets Acquired and Liabilities Assumed (Detail) HTML 65K
73: R59 Acquired Intangible Assets Amortization (Detail) HTML 45K
100: R60 Proforma Results (Detail) HTML 48K
48: R61 Fixed Assets (Detail) HTML 60K
51: R62 Depreciation and Amortization Expense (Detail) HTML 38K
109: R63 Goodwill and Intangible Assets (Detail) HTML 53K
105: R64 Goodwill and Intangible Assets - Additional HTML 44K
Information (Detail)
76: R65 Changes in Carrying Amount of Goodwill (Detail) HTML 54K
107: R66 Amortization Expense Related to Intangible Assets HTML 45K
(Detail)
47: R67 Estimated Future Amortization Expense for HTML 52K
Intangible Assets (Detail)
81: R68 Asset Impairment Charges - Additional Information HTML 40K
(Detail)
126: R69 Asset Impairment Charges (Detail) HTML 38K
23: R70 Accrued Expenses (Detail) HTML 46K
39: R71 Accrued Expenses - Additional Information (Detail) HTML 36K
66: R72 Debt Outstanding Excluding Capital Lease HTML 50K
Obligations (Detail)
30: R73 Interest Expense (Detail) HTML 49K
129: R74 Debt - Additional Information (Detail) HTML 189K
43: R75 Interest Expense on Convertible Senior Notes HTML 49K
(Detail)
34: R76 Summary of Future Payments under Notes and Senior HTML 62K
Secured Credit Facilities (Detail)
38: R77 Summary of Future Payments under Notes and Senior HTML 37K
Secured Credit Facilities (Parenthetical) (Detail)
25: R78 Geographic Breakdown of (Loss) Income Before HTML 43K
Benefit (Provision) for Income Taxes (Detail)
29: R79 Components of Benefit (Provision) for Income Taxes HTML 70K
(Detail)
91: R80 Income Taxes - Additional Information (Detail) HTML 108K
36: R81 Taxes Computed at Statutory Federal Income Tax HTML 92K
Rate Reconciled to Provision for Income Taxes
(Detail)
124: R82 Components of Deferred Tax Assets and Liabilities HTML 85K
(Detail)
63: R83 Deferred Tax Assets (Liabilities) Classified in HTML 52K
Consolidated Balance Sheets (Detail)
98: R84 Reconciliation of Unrecognized Tax Benefits HTML 53K
(Detail)
106: R85 Recognized Interest and Penalties Related to HTML 37K
Uncertain Tax Positions (Detail)
35: R86 Amount of Interest and Penalties Included in HTML 37K
Consolidated Balance Sheets (Detail)
37: R87 Stock Award Plans - Additional Information HTML 89K
(Detail)
121: R88 Stock-Based Compensation Expense (Detail) HTML 39K
31: R89 Activity for Restricted Stock Units (Detail) HTML 61K
92: R90 Activity for Restricted Stock Awards (Detail) HTML 56K
88: R91 Stock Options Outstanding (Detail) HTML 67K
110: R92 Weighted Average Grant Date Fair Value Information HTML 51K
and Related Valuation Assumptions (Detail)
87: R93 Stock Option Activity (Detail) HTML 41K
72: R94 Stock Option Awards (Detail) HTML 54K
115: R95 Stockholders' Equity - Additional Information HTML 84K
(Detail)
70: R96 Components of Accumulated Other Comprehensive HTML 60K
Income (Detail)
44: R97 Derivative Financial Instruments - Additional HTML 78K
Information (Detail)
79: R98 Activity Related to Interest Rate Swap Agreement HTML 51K
(Detail)
74: R99 Rent Expense (Detail) HTML 38K
56: R100 Future Commitments under Capital and Operating HTML 82K
Leases (Detail)
132: R101 Business Segments - Additional Information HTML 39K
(Detail)
108: R102 Revenues and Income from Operations Related to HTML 49K
Segment Within Reconciliation to Consolidated
Amounts (Detail)
86: R103 Supplemental Disclosure of Cash Flow Information HTML 40K
(Detail)
26: R104 Revenues by Geographic Area (Detail) HTML 41K
117: R105 Long-Lived Assets by Geographic Area (Detail) HTML 42K
125: R106 Contingencies - Additional Information (Detail) HTML 43K
119: R107 Commitment with Strategic Partner - Additional HTML 41K
Information (Detail)
82: R108 Expense Incurred Under Affiliated Computer HTML 38K
Services Agreement (Detail)
33: R109 North American Site Consolidation Plan - HTML 64K
Additional Information (Detail)
101: R110 Schedule II - Valuation And Qualifying Accounts HTML 46K
(Detail)
128: XML IDEA XML File -- Filing Summary XML 203K
22: EXCEL IDEA Workbook of Financial Reports XLSX 365K
52: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.88M
13: EX-101.INS XBRL Instance -- mdrx-20131231 XML 2.89M
15: EX-101.CAL XBRL Calculations -- mdrx-20131231_cal XML 367K
16: EX-101.DEF XBRL Definitions -- mdrx-20131231_def XML 936K
17: EX-101.LAB XBRL Labels -- mdrx-20131231_lab XML 2.10M
18: EX-101.PRE XBRL Presentations -- mdrx-20131231_pre XML 1.49M
14: EX-101.SCH XBRL Schema -- mdrx-20131231 XSD 302K
68: ZIP XBRL Zipped Folder -- 0001193125-14-080251-xbrl Zip 301K
| EX-10.31 |
Exhibit 10.31
Amendment No. 1 to
Performance-Based Restricted Stock Unit Award Agreement Dated December 24, 2012
THIS AMENDMENT to the Performance-Based Restricted Stock Unit Award Agreement (the “Agreement”), dated December 24, 2012, by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (“Company”), and Paul M. Black (“Black”), is effective as of February 28, 2014.
WHEREAS, the Company and Black previously entered into the Agreement, and now mutually wish to amend certain terms contained therein.
NOW THEREFORE, in consideration of the foregoing premises, it is agreed by and between the parties as follows:
1. Effective as of the date of this Amendment, the definition of “Total Shareholder Return” in Section 2.c. of Exhibit A to the Agreement is amended to read as follows:
c. “Total Shareholder Return” or “TSR” means total shareholder return as applied to the Company or any company in the Comparison Group, meaning stock price appreciation from the beginning to the end of the Performance Period, plus dividends and distributions made or declared (assuming such dividends or distributions are reinvested in the common stock of the Company or any company in the Comparison Group) during the Performance Period, expressed as a percentage return. Except as modified in Section 4(d), for purposes of computing TSR, the stock price at the beginning of the Performance Period will be the closing price of a share of common stock on the Grant Date, and the stock price at the end of the Performance Period will be the average price of a share of common stock over the 30 trading days ending on the last day of the Performance Period, adjusted for changes in capital structure; provided, however, that TSR will be negative one hundred percent (-100%) if a company: (i) files for bankruptcy, reorganization, or liquidation under any chapter of the U.S. Bankruptcy Code; (ii) is the subject of an involuntary bankruptcy proceeding that is not dismissed within 30 days; (iii) is the subject of a stockholder approved plan of liquidation or dissolution; or (iv) ceases to conduct substantial business operations.
2. Effective as of the date of this Amendment, Section 4.c. of Exhibit A to the Agreement is amended to read as follows:
c. For purposes of computing Total Shareholder Return for the Company and each other company in the Comparison Group, the stock price at the beginning and end of the Performance Period will, subject to Section 2 of the Performance-Based Restricted Stock Unit Award Agreement, be determined as the closing price of the stock on the Grant Date at the beginning of the Performance Period and the 30-day average closing price of the stock on the 30 consecutive trading days ending on and including the last day of the Performance Period for the end of the Performance Period.
(Signature Page Follows)
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed on the day and year first above written.
| ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. | ||
| By: | /s/ Brian Farley | |
| Name: Brian P. Farley | ||
| /s/ Paul Black | ||
| Paul M. Black | ||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/3/14 | |||
| 2/28/14 | 4 | |||
| For Period end: | 12/31/13 | ARS | ||
| 12/24/12 | 4 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/29/22 Veradigm Inc. 10-K/A 12/31/21 12:4M Donnelley … Solutions/FA 2/25/22 Veradigm Inc. 10-K 12/31/21 150:28M Donnelley … Solutions/FA 2/26/21 Veradigm Inc. 10-K 12/31/20 165:35M ActiveDisclosure/FA 9/29/14 SEC UPLOAD¶ 9/13/17 1:36K Veradigm Inc. 9/02/14 SEC UPLOAD¶ 9/13/17 1:137K Veradigm Inc. 8/01/14 SEC UPLOAD¶ 9/13/17 1:160K Veradigm Inc. |